KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

Insitro has signed three strategic agreements with Eli Lilly aimed at advancing treatments for metabolic diseases like MASLD, ...

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and ...

Companies to extend collaboration on DACRAs with an additional collaboration molecule and investigation of the DACRA platform within multiple indications LUGANO, Switzerland, Oct. 10, 2024 ...

Take a closer look at 12 biotech unicorns, with a worth of more than $1 billion, that are trying to revolutionize the ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing ...

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...

If all goes according to plan, insitro could finally start testing its first drug in clinical trials in 2026, eight years ...

908 Devices, Boston Alnylam Pharmaceuticals, Cambridge, MA BeiGene, Cambridge, MA Insitro, South San Francisco Kura Oncology, San Diego Ossium Health, San Francisco Roivant Sciences, New York This ...